These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2996808)

  • 1. Unaltered stimulation of pituitary adrenocorticotrophin secretion by corticotrophin-releasing factor following sodium valproate administration in a patient with Nelson's syndrome.
    Gomi M; Iida S; Itoh Y; Moriwaki K; Kanayama S; Namba M; Tarui S
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):123-7. PubMed ID: 2996808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of sodium valproate in the treatment of Nelson's syndrome.
    Dornhorst A; Jenkins JS; Lamberts SW; Abraham RR; Wynn V; Beckford U; Gillham B; Jones MT
    J Clin Endocrinol Metab; 1983 May; 56(5):985-91. PubMed ID: 6300181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cyproheptadine, desmethylcyproheptadine, gamma-amino-butyric acid and sodium valproate on adrenocorticotrophin secretion by cultured pituitary tumour cells from three patients with Nelson's syndrome.
    Lamberts SW; Verleun T; Bons EG; Uitterlinden P; Oosterom R
    J Endocrinol; 1983 Mar; 96(3):401-6. PubMed ID: 6300275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ovine corticotrophin releasing factor (oCRF), bromocriptine and TRH on the secretion of ACTH and alpha-MSH in Nelson's syndrome and Cushing's disease.
    Abraham RR; Campbell EA; Gillham B; Thody AJ; Altaher AR; Prysor-Jones A; Wynn V; Jones MT; Jenkins J
    Clin Endocrinol (Oxf); 1986 Jul; 25(1):75-85. PubMed ID: 3024873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sodium valproate on plasma ACTH and cortisol concentrations in Cushing's disease and Nelson's syndrome.
    Kasperlik-Załuska A; Drac-Kaniewska J; Migdalska B; Jeske W; Wiśniewska-Woźniak T
    Endokrynol Pol; 1988; 39(5):245-52. PubMed ID: 2855625
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of treatment with sodium valproate and diazepam on plasma corticotropin in Nelson's syndrome.
    Jones MT; Gillham B; Beckford U; Dornhorst A; Abraham RR; Seed M; Wynn V
    Lancet; 1981 May; 1(8231):1179-8. PubMed ID: 6112528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.
    Elias AN; Gwinup G; Valenta LJ
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):151-4. PubMed ID: 6273025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin-releasing hormone (CRH) stimulation in Nelson's syndrome: response of adrenocorticotropin secretion to pulse injection and continuous infusion of CRH.
    Oldfield EH; Schulte HM; Chrousos GP; Gold PW; Benker G; Peterson RE; Cutler GB; Loriaux DL
    J Clin Endocrinol Metab; 1986 May; 62(5):1020-6. PubMed ID: 3007552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
    Reincke M; Allolio B; Kaulen D; Jaursch-Hancke C; Winkelmann W
    Klin Wochenschr; 1988 Aug; 66(15):686-9. PubMed ID: 2845188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of Nelson's syndrome with sodium valproate.
    Kelly W; Adams JE; Laing I; Longson D; Davies D
    Clin Endocrinol (Oxf); 1988 Feb; 28(2):195-204. PubMed ID: 2844446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bromocriptine and cyproheptadine on basal and corticotropin-releasing factor (CRF)-induced ACTH release in a patient with Nelson's syndrome.
    Hirata Y; Nakashima H; Uchihashi M; Tomita M; Fujita T; Ikeda M
    Endocrinol Jpn; 1984 Oct; 31(5):619-26. PubMed ID: 6097444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome.
    Kasperlik-Załuska AA; Zgliczyński W; Jeske W; Zdunowski P
    Neuro Endocrinol Lett; 2005 Dec; 26(6):709-12. PubMed ID: 16380696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium valproate and Nelson's syndrome.
    Elias AN; Gwinup G
    Lancet; 1981 Aug; 2(8240):252-3. PubMed ID: 6114301
    [No Abstract]   [Full Text] [Related]  

  • 14. Size reduction of an ACTH-secreting pituitary macroadenoma in Nelson's syndrome by sodium valproate: effect of withdrawal and re-institution of treatment.
    Loli P; Berselli ME; Vignati F; De Grandi C; Tagliaferri M
    Acta Endocrinol (Copenh); 1988 Nov; 119(3):435-42. PubMed ID: 2847474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACTH secretory responsiveness of pituitary adrenotroph cell tumor to adrenocorticotropin-releasing factor in Cushing's disease and Nelson's syndrome.
    Takeda R; Ito T; Kawato M; Nakabayashi H; Miyamori I; Morise T; Koshida H; Ikeda M
    Exp Clin Endocrinol; 1986 Jun; 87(1):31-7. PubMed ID: 3017732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium-valproate administration on plasma ACTH levels in patients with ACTH hypersecretion.
    Ambrosi B; Bochicchio D; Riva E; Faglia G
    J Endocrinol Invest; 1983 Aug; 6(4):305-6. PubMed ID: 6315806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.
    Loli P; Berselli ME; Frascatani F; Muratori F; Tagliaferri M
    J Endocrinol Invest; 1984 Apr; 7(2):93-6. PubMed ID: 6327800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome.
    Mercado-Asis LB; Yanovski JA; Tracer HL; Chik CL; Cutler GB
    J Clin Endocrinol Metab; 1997 Feb; 82(2):514-7. PubMed ID: 9024246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
    Katznelson L
    J Clin Endocrinol Metab; 2013 May; 98(5):1803-7. PubMed ID: 23539733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of synthetic corticotropin-releasing factor in normal individuals and in patients with hypothalamic-pituitary-adrenocortical disorders.
    Jørgensen H; Skare S; Frey H; Hanssen KF; Norman N
    Acta Med Scand; 1985; 218(1):79-84. PubMed ID: 2996312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.